Application of Nuclear Medicine in Cancer Diagnosis and Treatment
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: 15 April 2025 | Viewed by 1085
Special Issue Editor
Interests: nuclear medicine; peptide receptor radionuclide therapy; endocrinology; oncology; computed tomography
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Nuclear medicine has rapidly advanced in recent times. In just thirty years, it has made two significant leaps forward and is now on the brink of another breakthrough that could significantly affect cancer treatment within the coming years.
In the 1990s, FDG-PET revolutionized nuclear medicine by using a radioactive glucose analogue to detect cancer cells, becoming the standard for detecting cancer. In the early 2000s, hybrid imaging techniques like PET/CT, SPECT/CT, and PET/MRI further advanced the field, combining different technologies to improve patient care and detection of abnormalities.
Nuclear imaging is entering a new era called theranostics, combining cancer diagnosis, monitoring, and treatment. This approach utilizes new radiopharmaceuticals that specifically bind to and destroy tumor cells, targeting difficult-to-treat cancers like gastroenteropancreatic neuroendocrine tumors and metastatic castration-resistant prostate cancer.
I invite researchers to address this topic, providing insightful findings on the known and new applications of nuclear medicine in cancer diagnosis and treatment.
Dr. Michele Klain
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PET/CT
- imaging
- nuclear medicine
- cancer diagnosis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
